Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Remicade Helped By “Slow Start” To Medicare Part B Demo

This article was originally published in The Pink Sheet Daily

Executive Summary

Johnson & Johnson's rheumatoid arthritis therapy Remicade is feeling virtually no impact from a Medicare demonstration project that provides coverage to competing agents, Group Chairman-Biopharmaceuticals Joe Scodari said during the Bear Stearns health care conference in New York Sept. 13

You may also be interested in...



Enbrel Psoriatic Arthritis Indication Added To Medicare Part B Demo

The Centers for Medicare & Medicaid Services has added coverage of Wyeth/Amgen's Enbrel (etanercept) for psoriatic arthritis to its Part B demonstration project

Enbrel Psoriatic Arthritis Indication Added To Medicare Part B Demo

The Centers for Medicare & Medicaid Services has added coverage of Wyeth/Amgen's Enbrel (etanercept) for psoriatic arthritis to its Part B demonstration project

Medicare Part B Average Sales Prices Will Be Published In December – CMS

2005 payment rates, which will be based on third quarter 2004 data supplied by manufacturers, will not be ready in time to be included in CMS's final Physician Fee Schedule rule, which the agency plans to release Nov. 1. The final rule will also include recommended billing code changes.

Topics

UsernamePublicRestriction

Register

OM004078

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel